Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 62 entries
Sorted by: Best Match Show Resources per page
Predictors of Storage Symptom Improvement after Plasma Kinetic Enucleation of the Prostate.

Urology

Mian A, Pachorek M, Sam AP, Ruel NH, Yang DD, Kohler DT, Warner DJ.
PMID: 34813839
Urology. 2021 Nov 20; doi: 10.1016/j.urology.2021.11.008. Epub 2021 Nov 20.

OBJECTIVE: To investigate which preoperative findings portend poor improvement in storage symptoms in patients undergoing plasma kinetic enucleation of prostate (PKEP).METHODS: A single surgeon series of patients who had undergone PKEP with minimum one year follow up were evaluated....

Cite
Mian A, Pachorek M, Sam AP, et al. Predictors of Storage Symptom Improvement after Plasma Kinetic Enucleation of the Prostate. Urology. 2021;doi: 10.1016/j.urology.2021.11.008.
Mian, A., Pachorek, M., Sam, A. P., Ruel, N. H., Yang, D. D., Kohler, D. T., & Warner, D. J. (2021). Predictors of Storage Symptom Improvement after Plasma Kinetic Enucleation of the Prostate. Urology, . https://doi.org/10.1016/j.urology.2021.11.008
Mian, Abrar, et al. "Predictors of Storage Symptom Improvement after Plasma Kinetic Enucleation of the Prostate." Urology vol. (2021). doi: https://doi.org/10.1016/j.urology.2021.11.008
Mian A, Pachorek M, Sam AP, Ruel NH, Yang DD, Kohler DT, Warner DJ. Predictors of Storage Symptom Improvement after Plasma Kinetic Enucleation of the Prostate. Urology. 2021 Nov 20; doi: 10.1016/j.urology.2021.11.008. Epub 2021 Nov 20. PMID: 34813839.
Copy Download .nbib Format: NLM
Sweat monitoring beneath garments using passive, wireless resonant sensors interfaced with laser-ablated microfluidics.

NPJ digital medicine

Carr AR, Patel YH, Neff CR, Charkhabi S, Kallmyer NE, Angus HF, Reuel NF.
PMID: 32377573
NPJ Digit Med. 2020 Apr 30;3:62. doi: 10.1038/s41746-020-0270-2. eCollection 2020.

Sweat loss can help determine hydration status of individuals working in harsh conditions, which is especially relevant to those who wear thick personal protective equipment (PPE) such as firefighters. A wireless, passive, conformable sweat sensor sticker is described here...

Cite
Carr AR, Patel YH, Neff CR, et al. Sweat monitoring beneath garments using passive, wireless resonant sensors interfaced with laser-ablated microfluidics. NPJ Digit Med. 2020;3:62doi: 10.1038/s41746-020-0270-2.
Carr, A. R., Patel, Y. H., Neff, C. R., Charkhabi, S., Kallmyer, N. E., Angus, H. F., & Reuel, N. F. (2020). Sweat monitoring beneath garments using passive, wireless resonant sensors interfaced with laser-ablated microfluidics. NPJ digital medicine, 362. https://doi.org/10.1038/s41746-020-0270-2
Carr, Adam R, et al. "Sweat monitoring beneath garments using passive, wireless resonant sensors interfaced with laser-ablated microfluidics." NPJ digital medicine vol. 3 (2020): 62. doi: https://doi.org/10.1038/s41746-020-0270-2
Carr AR, Patel YH, Neff CR, Charkhabi S, Kallmyer NE, Angus HF, Reuel NF. Sweat monitoring beneath garments using passive, wireless resonant sensors interfaced with laser-ablated microfluidics. NPJ Digit Med. 2020 Apr 30;3:62. doi: 10.1038/s41746-020-0270-2. eCollection 2020. PMID: 32377573; PMCID: PMC7193562.
Copy Download .nbib Format: NLM
Meals in the melting-pot: Immigration and dietary change in diversifying cities.

Appetite

Rule NF, Dring CC, Thornton TF.
PMID: 34606941
Appetite. 2022 Jan 01;168:105728. doi: 10.1016/j.appet.2021.105728. Epub 2021 Oct 02.

Changes in diets and food practices have implications for personal and planetary health. As these implications have become more apparent, dietary change interventions that seek to promote healthy and sustainable transitions have proliferated, and the processes and drivers of...

Cite
Rule NF, Dring CC, Thornton TF. Meals in the melting-pot: Immigration and dietary change in diversifying cities. Appetite. 2021;168:105728doi: 10.1016/j.appet.2021.105728.
Rule, N. F., Dring, C. C., & Thornton, T. F. (2022). Meals in the melting-pot: Immigration and dietary change in diversifying cities. Appetite, 168105728. https://doi.org/10.1016/j.appet.2021.105728
Rule, Nicola Frances, et al. "Meals in the melting-pot: Immigration and dietary change in diversifying cities." Appetite vol. 168 (2022): 105728. doi: https://doi.org/10.1016/j.appet.2021.105728
Rule NF, Dring CC, Thornton TF. Meals in the melting-pot: Immigration and dietary change in diversifying cities. Appetite. 2022 Jan 01;168:105728. doi: 10.1016/j.appet.2021.105728. Epub 2021 Oct 02. PMID: 34606941.
Copy Download .nbib Format: NLM
Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate.

Journal of endourology

Mian A, Balzano FL, Pachorek M, Sam AP, Ruel N, Warner JN.
PMID: 35018807
J Endourol. 2022 Jan 12; doi: 10.1089/end.2021.0911. Epub 2022 Jan 12.

BACKGROUND Lower urinary tract symptoms among adult men can significantly impact quality of life. We evaluated complications based on prostate size following plasma kinetic enucleation of the prostate. METHODS Patients were grouped into small prostate group (SPG) 75 grams...

Cite
Mian A, Balzano FL, Pachorek M, et al. Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate. J Endourol. 2022;doi: 10.1089/end.2021.0911.
Mian, A., Balzano, F. L., Pachorek, M., Sam, A. P., Ruel, N., & Warner, J. N. (2022). Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate. Journal of endourology, . https://doi.org/10.1089/end.2021.0911
Mian, Abrar, et al. "Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate." Journal of endourology vol. (2022). doi: https://doi.org/10.1089/end.2021.0911
Mian A, Balzano FL, Pachorek M, Sam AP, Ruel N, Warner JN. Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate. J Endourol. 2022 Jan 12; doi: 10.1089/end.2021.0911. Epub 2022 Jan 12. PMID: 35018807.
Copy Download .nbib Format: NLM
Tuberculosis Screening in Silica-Exposed Workers : Developing a Tool for Health Care Providers.

Public health reports (Washington, D.C. : 1974)

Reul NK, Gray Z, Braid BB, Leland MA.
PMID: 34499541
Public Health Rep. 2021 Sep 09;333549211041584. doi: 10.1177/00333549211041584. Epub 2021 Sep 09.

Both the Occupational Safety and Health Administration and Washington State require safety and health protections for workers exposed to respirable crystalline silica, including tuberculosis (TB) screening as part of occupational medical surveillance. We describe the creation of a TB...

Cite
Reul NK, Gray Z, Braid BB, et al. Tuberculosis Screening in Silica-Exposed Workers : Developing a Tool for Health Care Providers. Public Health Rep. 2021;333549211041584doi: 10.1177/00333549211041584.
Reul, N. K., Gray, Z., Braid, B. B., & Leland, M. A. (2021). Tuberculosis Screening in Silica-Exposed Workers : Developing a Tool for Health Care Providers. Public health reports (Washington, D.C. : 1974), 333549211041584. https://doi.org/10.1177/00333549211041584
Reul, Nicholas K, et al. "Tuberculosis Screening in Silica-Exposed Workers : Developing a Tool for Health Care Providers." Public health reports (Washington, D.C. : 1974) vol. (2021): 333549211041584. doi: https://doi.org/10.1177/00333549211041584
Reul NK, Gray Z, Braid BB, Leland MA. Tuberculosis Screening in Silica-Exposed Workers : Developing a Tool for Health Care Providers. Public Health Rep. 2021 Sep 09;333549211041584. doi: 10.1177/00333549211041584. Epub 2021 Sep 09. PMID: 34499541.
Copy Download .nbib Format: NLM
A revision of .

IMA fungus

Bennett RM, Devanadera MK, Dedeles GR.
PMID: 30622882
IMA Fungus. 2018 Jul;9:259-269. doi: 10.5598/imafungus.2018.09.02.03. Epub 2018 Aug 29.

The genus

Cite
Bennett RM, Devanadera MK, Dedeles GR. A revision of . IMA Fungus. 2018;9:259-269doi: 10.5598/imafungus.2018.09.02.03.
Bennett, R. M., Devanadera, M. K., & Dedeles, G. R. (2018). A revision of . IMA fungus, 9259-269. https://doi.org/10.5598/imafungus.2018.09.02.03
Bennett, Reuel M, et al. "A revision of ." IMA fungus vol. 9 (2018): 259-269. doi: https://doi.org/10.5598/imafungus.2018.09.02.03
Bennett RM, Devanadera MK, Dedeles GR. A revision of . IMA Fungus. 2018 Jul;9:259-269. doi: 10.5598/imafungus.2018.09.02.03. Epub 2018 Aug 29. PMID: 30622882; PMCID: PMC6317584.
Copy Download .nbib Format: NLM
1α,25-Dihydroxyvitamin D(3) down-regulates pleiotrophin messenger RNA expression in osteoblast-like cells.

Endocrine

Tamura M, Ichikawa F, Guillerman RP, Deuel TF, Nodal M.
PMID: 21153232
Endocrine. 1995 Jan;3(1):21-4. doi: 10.1007/BF02917444.

Pleiotrophin (PTN)[heparin-binding-growth-associated molecule (HB-GAM), heparin-binding neurite-promoting factor (HBNF)] is a recently identified polypeptide that stimulates growth of fibroblasts and enhances neurite extension. PTN is expressed in many tissues but relatively high level of expression has been observed in brain...

Cite
Tamura M, Ichikawa F, Guillerman RP, et al. 1α,25-Dihydroxyvitamin D(3) down-regulates pleiotrophin messenger RNA expression in osteoblast-like cells. Endocrine. 1995;3(1):21-4doi: 10.1007/BF02917444.
Tamura, M., Ichikawa, F., Guillerman, R. P., Deuel, T. F., & Nodal, M. (1995). 1α,25-Dihydroxyvitamin D(3) down-regulates pleiotrophin messenger RNA expression in osteoblast-like cells. Endocrine, 3(1), 21-4. https://doi.org/10.1007/BF02917444
Tamura, M, et al. "1α,25-Dihydroxyvitamin D(3) down-regulates pleiotrophin messenger RNA expression in osteoblast-like cells." Endocrine vol. 3,1 (1995): 21-4. doi: https://doi.org/10.1007/BF02917444
Tamura M, Ichikawa F, Guillerman RP, Deuel TF, Nodal M. 1α,25-Dihydroxyvitamin D(3) down-regulates pleiotrophin messenger RNA expression in osteoblast-like cells. Endocrine. 1995 Jan;3(1):21-4. doi: 10.1007/BF02917444. PMID: 21153232.
Copy Download .nbib Format: NLM
Bi- and trilayer graphene solutions.

Nature nanotechnology

Shih CJ, Vijayaraghavan A, Krishnan R, Sharma R, Han JH, Ham MH, Jin Z, Lin S, Paulus GL, Reuel NF, Wang QH, Blankschtein D, Strano MS.
PMID: 21706026
Nat Nanotechnol. 2011 Jun 26;6(7):439-45. doi: 10.1038/nnano.2011.94.

Bilayer and trilayer graphene with controlled stacking is emerging as one of the most promising candidates for post-silicon nanoelectronics. However, it is not yet possible to produce large quantities of bilayer or trilayer graphene with controlled stacking, as is...

Cite
Shih CJ, Vijayaraghavan A, Krishnan R, et al. Bi- and trilayer graphene solutions. Nat Nanotechnol. 2011;6(7):439-45doi: 10.1038/nnano.2011.94.
Shih, C. J., Vijayaraghavan, A., Krishnan, R., Sharma, R., Han, J. H., Ham, M. H., Jin, Z., Lin, S., Paulus, G. L., Reuel, N. F., Wang, Q. H., Blankschtein, D., & Strano, M. S. (2011). Bi- and trilayer graphene solutions. Nature nanotechnology, 6(7), 439-45. https://doi.org/10.1038/nnano.2011.94
Shih, Chih-Jen, et al. "Bi- and trilayer graphene solutions." Nature nanotechnology vol. 6,7 (2011): 439-45. doi: https://doi.org/10.1038/nnano.2011.94
Shih CJ, Vijayaraghavan A, Krishnan R, Sharma R, Han JH, Ham MH, Jin Z, Lin S, Paulus GL, Reuel NF, Wang QH, Blankschtein D, Strano MS. Bi- and trilayer graphene solutions. Nat Nanotechnol. 2011 Jun 26;6(7):439-45. doi: 10.1038/nnano.2011.94. PMID: 21706026.
Copy Download .nbib Format: NLM
Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California.

Cancer medicine

Salgia NJ, Chehrazi-Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK.
PMID: 34331372
Cancer Med. 2021 Aug;10(16):5671-5680. doi: 10.1002/cam4.4119. Epub 2021 Jul 31.

BACKGROUND: Tertiary cancer centers offer clinical expertise and multi-modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better understanding of the relationships between tertiary and community practice...

Cite
Salgia NJ, Chehrazi-Raffle A, Hsu J, et al. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Med. 2021;10(16):5671-5680doi: 10.1002/cam4.4119.
Salgia, N. J., Chehrazi-Raffle, A., Hsu, J., Zengin, Z., Salgia, S., Chawla, N. S., Meza, L., Malhotra, J., Dizman, N., Muddasani, R., Ruel, N., Cianfrocca, M., Gong, J., Anand, S., Chiu, V., Yeh, J., & Pal, S. K. (2021). Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer medicine, 10(16), 5671-5680. https://doi.org/10.1002/cam4.4119
Salgia, Nicholas J, et al. "Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California." Cancer medicine vol. 10,16 (2021): 5671-5680. doi: https://doi.org/10.1002/cam4.4119
Salgia NJ, Chehrazi-Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Med. 2021 Aug;10(16):5671-5680. doi: 10.1002/cam4.4119. Epub 2021 Jul 31. PMID: 34331372; PMCID: PMC8366095.
Copy Download .nbib Format: NLM
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (.

Frontiers in oncology

Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN.
PMID: 30915273
Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.

No abstract available.

Cite
Reckamp KL, Frankel PH, Ruel N, et al. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (. Front Oncol. 2019;9:132doi: 10.3389/fonc.2019.00132.
Reckamp, K. L., Frankel, P. H., Ruel, N., Mack, P. C., Gitlitz, B. J., Li, T., Koczywas, M., Gadgeel, S. M., Cristea, M. C., Belani, C. P., Newman, E. M., Gandara, D. R., & Lara, P. N. (2019). Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (. Frontiers in oncology, 9132. https://doi.org/10.3389/fonc.2019.00132
Reckamp, Karen L, et al. "Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (." Frontiers in oncology vol. 9 (2019): 132. doi: https://doi.org/10.3389/fonc.2019.00132
Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (. Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019. PMID: 30915273; PMCID: PMC6421302.
Copy Download .nbib Format: NLM
Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials.

JNCI cancer spectrum

Sedhom R, Ferrell B, Ruel N, Koczywas M, Chung V, Smith TJ.
PMID: 33392443
JNCI Cancer Spectr. 2020 Aug 14;4(6):pkaa067. doi: 10.1093/jncics/pkaa067. eCollection 2020 Dec.

BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life...

Cite
Sedhom R, Ferrell B, Ruel N, et al. Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. JNCI Cancer Spectr. 2020;4(6):pkaa067doi: 10.1093/jncics/pkaa067.
Sedhom, R., Ferrell, B., Ruel, N., Koczywas, M., Chung, V., & Smith, T. J. (2020). Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. JNCI cancer spectrum, 4(6), pkaa067. https://doi.org/10.1093/jncics/pkaa067
Sedhom, Ramy, et al. "Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials." JNCI cancer spectrum vol. 4,6 (2020): pkaa067. doi: https://doi.org/10.1093/jncics/pkaa067
Sedhom R, Ferrell B, Ruel N, Koczywas M, Chung V, Smith TJ. Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. JNCI Cancer Spectr. 2020 Aug 14;4(6):pkaa067. doi: 10.1093/jncics/pkaa067. eCollection 2020 Dec. PMID: 33392443; PMCID: PMC7768928.
Copy Download .nbib Format: NLM
Salt-Sensitive Hypertension, Renal Injury, and Renal Vasodysfunction Associated With Dahl Salt-Sensitive Rats Are Abolished in Consomic SS.BN1 Rats.

Journal of the American Heart Association

Potter JC, Whiles SA, Miles CB, Whiles JB, Mitchell MA, Biederman BE, Dawoud FM, Breuel KF, Williamson GA, Picken MM, Polichnowski AJ.
PMID: 34689582
J Am Heart Assoc. 2021 Nov 02;10(21):e020261. doi: 10.1161/JAHA.120.020261. Epub 2021 Oct 23.

Background Abnormal renal hemodynamic responses to salt-loading are thought to contribute to salt-sensitive (SS) hypertension. However, this is based largely on studies in anesthetized animals, and little data are available in conscious SS and salt-resistant rats. Methods and Results...

Cite
Potter JC, Whiles SA, Miles CB, et al. Salt-Sensitive Hypertension, Renal Injury, and Renal Vasodysfunction Associated With Dahl Salt-Sensitive Rats Are Abolished in Consomic SS.BN1 Rats. J Am Heart Assoc. 2021;10(21):e020261doi: 10.1161/JAHA.120.020261.
Potter, J. C., Whiles, S. A., Miles, C. B., Whiles, J. B., Mitchell, M. A., Biederman, B. E., Dawoud, F. M., Breuel, K. F., Williamson, G. A., Picken, M. M., & Polichnowski, A. J. (2021). Salt-Sensitive Hypertension, Renal Injury, and Renal Vasodysfunction Associated With Dahl Salt-Sensitive Rats Are Abolished in Consomic SS.BN1 Rats. Journal of the American Heart Association, 10(21), e020261. https://doi.org/10.1161/JAHA.120.020261
Potter, Jacqueline C, et al. "Salt-Sensitive Hypertension, Renal Injury, and Renal Vasodysfunction Associated With Dahl Salt-Sensitive Rats Are Abolished in Consomic SS.BN1 Rats." Journal of the American Heart Association vol. 10,21 (2021): e020261. doi: https://doi.org/10.1161/JAHA.120.020261
Potter JC, Whiles SA, Miles CB, Whiles JB, Mitchell MA, Biederman BE, Dawoud FM, Breuel KF, Williamson GA, Picken MM, Polichnowski AJ. Salt-Sensitive Hypertension, Renal Injury, and Renal Vasodysfunction Associated With Dahl Salt-Sensitive Rats Are Abolished in Consomic SS.BN1 Rats. J Am Heart Assoc. 2021 Nov 02;10(21):e020261. doi: 10.1161/JAHA.120.020261. Epub 2021 Oct 23. PMID: 34689582; PMCID: PMC8751849.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 62 entries